Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
IDEX Biometrics ASA is a Norwegian public limited company specializing in fingerprint imaging, recognition, and authentication technology. It develops and commercializes advanced biometric solutions, including sensors, modules, and enrollment systems, optimized for embedding into smart cards, payment cards, access control devices, and other secure products. The company's proprietary technologies, such as SmartFinger Film and TrustedBio sensors, enable offline, vault-level security for payments, identity verification, and physical-digital access, certified by Visa, Mastercard, FIDO Alliance, and EMVCo. IDEX Biometrics ASA serves banks, enterprises, public sectors, and issuers globally across Europe, Middle East, Africa, Americas, and Asia-Pacific through partnerships with firms like IDEMIA, Infineon, and Hengbao. Headquartered in Fornebu, Norway, with subsidiaries in the US, UK, and China, it focuses on identity-first biometrics to enhance user-friendliness, privacy, and resistance to phishing and AI attacks in financial and security markets.
NOK 8.24
+NOK 0.14 (+1.73%)
EOD Jul 2, 2026
The business is unprofitable at the operating level (-4147.24% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 203.7%, still solid. Margins contracted 1657.8pp, which offsets some of the top-line progress.
ROIC dropped from -233.21% to -405.82%, capital efficiency is deteriorating. Negative free cash flow of -NOK 87M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 3M
▲ +203.7% YoY
Net Income (TTM)
-NOK 97M
▼ -596.1% YoY
Op. Margin
-3027.34%
▼ -1657.8pp YoY
ROIC
-405.82%
▼ -172.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 70M
▼ -394.5% YoY
Op. Cash Flow (TTM)
-NOK 66M
▼ -395.2% YoY
Net Debt
NOK 12M
Cash & Equiv.
NOK 7M
3Y CAGR: -14.5%
Continue Research
IDEX Biometrics ASA (IDEX.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, IDEX Biometrics ASA scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
IDEX Biometrics ASA scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -3,027.3% operating margin and a -405.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh IDEX.XOSL's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.